Real life benralizumab effectiveness in patients with severe eosinophilic asthma after a 24 month observation

G. Lo Muzio (Roma (RM), Italy), O. Calò (Roma (RM), Italy), C. Cisternino (Roma (RM), Italy), P. Scarano (Roma (RM), Italy), A. Sanna (Roma (RM), Italy), F. De Filippis (Roma (RM), Italy), A. Steffanina (Roma (RM), Italy), M. Leporini (Roma (RM), Italy), P. Palange (Roma (RM), Italy), E. Graziani (Roma (RM), Italy)

Source: International Congress 2022 – Asthma biologics in real life studies
Session: Asthma biologics in real life studies
Session type: Thematic Poster
Number: 2398

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Lo Muzio (Roma (RM), Italy), O. Calò (Roma (RM), Italy), C. Cisternino (Roma (RM), Italy), P. Scarano (Roma (RM), Italy), A. Sanna (Roma (RM), Italy), F. De Filippis (Roma (RM), Italy), A. Steffanina (Roma (RM), Italy), M. Leporini (Roma (RM), Italy), P. Palange (Roma (RM), Italy), E. Graziani (Roma (RM), Italy). Real life benralizumab effectiveness in patients with severe eosinophilic asthma after a 24 month observation. 2398

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.